toripalimab
coherus,Shanghai Junshi Bioscience,coherus
['toripalimab', 'sclc', 'nsclc', 'choice-01']
excellent review by phd wu at #asco23 on the choice-01 study, where toripalimab + ct provided a significant os benefit over ct alone with a manageable safety profile, supporting the use of toripalimab + ct as 1st line tx for patients with advanced nsclc without egfr/alk mutations 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.